Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: D'Angelo, Christopher
Contact Information:
Sarah Snook
sarah.snook@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT04771078?term=NCT04771078&rank=1
Summary
Primary Objective
The primary objective of the study is to assess the safety of nonconforming ide-cel.
Secondary Objective
The secondary objective of the study is to assess the efficacy of nonconforming ide-cel.
Exploratory Objective (s)
Exploratory objectives of the study are to assess duration of response (DOR), progression-free survival (PFS) and overall survival (OS).